Canaccord Genuity Initiates Coverage On Maze Therapeutics with Buy Rating, Announces Price Target of $75

Canaccord Genuity analyst Whitney Ijem has initiated coverage on Maze Therapeutics (NASDAQ: MAZE) with a Buy rating. The firm has set a price target of $75 for the stock.